{"id":"botulinum-toxin-a-open-label","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site pain or bruising"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Muscle weakness or paralysis (off-target)"},{"rate":"1-3","effect":"Ptosis (eyelid drooping)"},{"rate":"1-5","effect":"Dry mouth"},{"rate":"5-10","effect":"Neck pain"},{"rate":"1-3","effect":"Antibody formation (neutralizing)"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Botulinum Toxin A is a neurotoxin that irreversibly cleaves SNARE proteins (specifically SNAP-25) required for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission, resulting in temporary flaccid paralysis of injected muscles. The effect is reversible over 3-4 months as new nerve terminals form and acetylcholine signaling is restored.","oneSentence":"Botulinum Toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:45.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Hemifacial spasm"},{"name":"Chronic migraine"},{"name":"Spasticity"},{"name":"Hyperhidrosis"},{"name":"Cosmetic wrinkle reduction"}]},"trialDetails":[{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT07489430","phase":"PHASE2","title":"DaxibotulinumtoxinA for Blepharospasm","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-07-01","conditions":"Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid","enrollment":20},{"nctId":"NCT03992404","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2019-09-16","conditions":"Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury","enrollment":603},{"nctId":"NCT07478822","phase":"PHASE3","title":"A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity","status":"RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2026-03-20","conditions":"Upper Limb Spasticity","enrollment":300},{"nctId":"NCT07473635","phase":"NA","title":"Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study","status":"RECRUITING","sponsor":"Bo Biering-Soerensen","startDate":"2026-01-07","conditions":"CRPS (Complex Regional Pain Syndromes), CRPS (Complex Regional Pain Syndrome) Type I, CRPS Type II","enrollment":20},{"nctId":"NCT06585696","phase":"PHASE3","title":"A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)","status":"COMPLETED","sponsor":"Cutia Therapeutics（Wuxi）Co.,Ltd","startDate":"2024-06-11","conditions":"Glabellar Frown Lines","enrollment":554},{"nctId":"NCT06387394","phase":"PHASE3","title":"A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-04-22","conditions":"Masseter Muscle Prominence","enrollment":202},{"nctId":"NCT06068855","phase":"PHASE3","title":"A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-10-17","conditions":"Masseter Muscle Prominence","enrollment":249},{"nctId":"NCT05028569","phase":"PHASE3","title":"Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-11-05","conditions":"Episodic Migraine","enrollment":775},{"nctId":"NCT06218251","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-02-05","conditions":"Upper Facial Lines","enrollment":100},{"nctId":"NCT07242300","phase":"PHASE3","title":"Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .","status":"NOT_YET_RECRUITING","sponsor":"JHM BioPharma (Tonghua) Co. , Ltd.","startDate":"2026-01","conditions":"Upper Limb Spasticity (ULS)","enrollment":207},{"nctId":"NCT06399718","phase":"PHASE3","title":"A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-04-30","conditions":"Masseter Muscle Prominence","enrollment":207},{"nctId":"NCT06937944","phase":"PHASE3","title":"Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines","status":"RECRUITING","sponsor":"JHM BioPharma (Tonghua) Co. , Ltd.","startDate":"2025-04-30","conditions":"Moderate to Severe Glabellar Lines","enrollment":669},{"nctId":"NCT05013424","phase":"PHASE2","title":"A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-09-01","conditions":"Glabellar Lines","enrollment":92},{"nctId":"NCT03985982","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2019-04-29","conditions":"Glabellar Frown Lines","enrollment":410},{"nctId":"NCT05216263","phase":"PHASE3","title":"Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-03-22","conditions":"Chronic Migraine","enrollment":75},{"nctId":"NCT05141006","phase":"PHASE2","title":"Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-03-29","conditions":"Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)","enrollment":83},{"nctId":"NCT02677805","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2016-03-30","conditions":"Glabellar Frown Lines","enrollment":251},{"nctId":"NCT02677298","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2016-03-02","conditions":"Glabellar Frown Lines","enrollment":784},{"nctId":"NCT06878482","phase":"PHASE4","title":"Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-17","conditions":"Chronic Ulcer of Lower Extremity, Wound, Botulinum Toxins, Type A","enrollment":15},{"nctId":"NCT06336785","phase":"PHASE4","title":"Kiss and Smile HIT (Holistic Individualized Treatment)","status":"COMPLETED","sponsor":"Erevna Innovations Inc.","startDate":"2023-11-02","conditions":"Aesthetic","enrollment":24},{"nctId":"NCT06785844","phase":"EARLY_PHASE1","title":"Intra-rectal Botulinum Toxin Injection for Intractable Non-retentive Fecal Incontinence in Children - an Open Label Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Shaare Zedek Medical Center","startDate":"2025-02-01","conditions":"Fecal Incontinence","enrollment":14},{"nctId":"NCT05134649","phase":"PHASE3","title":"A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-11-16","conditions":"Platysma Prominence","enrollment":292},{"nctId":"NCT05647551","phase":"PHASE4","title":"A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-01-05","conditions":"Facial Corrections, Facial Lines","enrollment":73},{"nctId":"NCT06583486","phase":"PHASE3","title":"A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Moderate to Severe Glabellar Lines","enrollment":488},{"nctId":"NCT06133491","phase":"","title":"Open Label, 6-month Study for High Frequency and Chronic Migraine,","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ki Health Partners. LLC","startDate":"2023-10-18","conditions":"Chronic Migraine, Headache","enrollment":20},{"nctId":"NCT04871451","phase":"PHASE2","title":"Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-07-27","conditions":"Cervical Dystonia","enrollment":51},{"nctId":"NCT05426161","phase":"PHASE4","title":"The Effect of Subcutaneous Injection of Botulinum Toxin A on Chronic Wound Pain in Lower Extremities","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2023-02-07","conditions":"Chronic Pain, Lower Extremity Wound","enrollment":10},{"nctId":"NCT04622254","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-11-12","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":368},{"nctId":"NCT05284019","phase":"PHASE4","title":"Real World Effectiveness of Eptinezumab in Participants With Migraine","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2022-03-04","conditions":"Migraine","enrollment":32},{"nctId":"NCT06420986","phase":"NA","title":"Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2021-08-12","conditions":"Hemorrhoids Third Degree","enrollment":50},{"nctId":"NCT06154070","phase":"","title":"An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ki Health Partners. LLC","startDate":"2023-10-24","conditions":"Migraine Disorders","enrollment":10},{"nctId":"NCT04594213","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-09-23","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":362},{"nctId":"NCT04766723","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2021-02-24","conditions":"Essential Tremor of the Upper Limb","enrollment":78},{"nctId":"NCT05485207","phase":"EARLY_PHASE1","title":"Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2022-04-04","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":5},{"nctId":"NCT06161246","phase":"PHASE4","title":"A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2023-10-23","conditions":"Injection Site Discomfort","enrollment":60},{"nctId":"NCT03806933","phase":"PHASE2","title":"Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Aesthetics GmbH","startDate":"2019-01-23","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":241},{"nctId":"NCT06036043","phase":"","title":"Botulinum Toxin for Chronic Neuropathic Pain","status":"UNKNOWN","sponsor":"Region Zealand","startDate":"2023-08-01","conditions":"Neuralgia, Chronic Pain","enrollment":12},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT04259086","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-12-06","conditions":"Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)","enrollment":48},{"nctId":"NCT04225260","phase":"PHASE3","title":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-01-27","conditions":"Glabellar Lines, Lateral Canthal Lines","enrollment":902},{"nctId":"NCT04815967","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","status":"UNKNOWN","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2021-11-16","conditions":"Spasticity, Cerebrovascular Accident, Multiple Sclerosis","enrollment":272},{"nctId":"NCT03786770","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-01-24","conditions":"Frown Lines","enrollment":61},{"nctId":"NCT01486264","phase":"PHASE4","title":"Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2012-01-20","conditions":"Cervical Dystonia","enrollment":283},{"nctId":"NCT03236012","phase":"PHASE1","title":"Hyperhidrosis in Patients With Amputations-Botox","status":"COMPLETED","sponsor":"University of Utah","startDate":"2019-01-08","conditions":"Hyperhidrosis","enrollment":25},{"nctId":"NCT03346252","phase":"EARLY_PHASE1","title":"The Effect of Botulinum Toxin A on Headache Attributed to TMD","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2017-05-08","conditions":"Secondary Headache Disorder","enrollment":20},{"nctId":"NCT01251380","phase":"PHASE3","title":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Cerebral Palsy, Muscle Spasticity, Children","enrollment":216},{"nctId":"NCT01251367","phase":"PHASE3","title":"Dysport® Adult Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-06","conditions":"Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury","enrollment":352},{"nctId":"NCT00288509","phase":"PHASE3","title":"Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-02","conditions":"Cervical Dystonia","enrollment":108},{"nctId":"NCT01313312","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity Extension Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-11","conditions":"Nervous System Disorders","enrollment":258},{"nctId":"NCT01261611","phase":"PHASE3","title":"Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-04","conditions":"Cervical Dystonia","enrollment":382},{"nctId":"NCT02493946","phase":"PHASE3","title":"Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-04","conditions":"Glabellar Lines","enrollment":600},{"nctId":"NCT03687736","phase":"PHASE4","title":"Subject Satisfaction With AbobutulinumtoxinA Treatment","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2018-10-02","conditions":"Glabellar Frown Lines","enrollment":120},{"nctId":"NCT03004248","phase":"PHASE3","title":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2016-12-09","conditions":"Glabellar Frown Lines","enrollment":2691},{"nctId":"NCT05162300","phase":"PHASE4","title":"Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles","status":"COMPLETED","sponsor":"Vitality Institute Medical Products","startDate":"2021-12-08","conditions":"Photoaging, Wrinkle, Sun Damaged Skin","enrollment":30},{"nctId":"NCT05340439","phase":"PHASE2","title":"INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2022-06","conditions":"Spastic Cerebral Palsy","enrollment":30},{"nctId":"NCT03617367","phase":"PHASE3","title":"Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2018-09-05","conditions":"Cervical Dystonia","enrollment":357},{"nctId":"NCT04631588","phase":"PHASE1","title":"Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2020-11-16","conditions":"Facial Fine Lines","enrollment":172},{"nctId":"NCT01780636","phase":"PHASE2, PHASE3","title":"Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome","status":"TERMINATED","sponsor":"Karen Noblett","startDate":"2013-01","conditions":"Non-relaxing Puborectalis Syndrome","enrollment":7},{"nctId":"NCT02270736","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2015-02-09","conditions":"Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke","enrollment":256},{"nctId":"NCT01994109","phase":"PHASE3","title":"Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2013-11","conditions":"Sialorrhea","enrollment":187},{"nctId":"NCT02610868","phase":"PHASE3","title":"Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2015-10","conditions":"Sialorrhea","enrollment":187},{"nctId":"NCT03569098","phase":"PHASE2","title":"Dysport in Hallux Abducto Valgus (HAV) Phase IIa","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-06-19","conditions":"Hallux Abducto Valgus","enrollment":186},{"nctId":"NCT00512135","phase":"PHASE3","title":"Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2007-06-18","conditions":"Glabellar Lines","enrollment":801},{"nctId":"NCT04143815","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2019-05-20","conditions":"Glabellar Frown Lines","enrollment":200},{"nctId":"NCT04143854","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2019-05-21","conditions":"Lateral Canthal Lines","enrollment":150},{"nctId":"NCT04792398","phase":"PHASE4","title":"Bruxism Xeomin® Intervention Trial","status":"UNKNOWN","sponsor":"Dominik Ettlin","startDate":"2021-05-01","conditions":"Sleep Bruxism, Adult","enrollment":6},{"nctId":"NCT02820844","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-10","conditions":"Urinary Bladder, Overactive","enrollment":250},{"nctId":"NCT03289169","phase":"PHASE4","title":"Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2016-12-30","conditions":"Glabellar Frown Lines","enrollment":300},{"nctId":"NCT04281745","phase":"PHASE4","title":"Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®","status":"UNKNOWN","sponsor":"Medy-Tox","startDate":"2019-10-17","conditions":"Glabellar Frown Lines","enrollment":200},{"nctId":"NCT03261167","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-02","conditions":"Spasticity, Post-Stroke","enrollment":124},{"nctId":"NCT01603615","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-10-30","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":220},{"nctId":"NCT01603641","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11-05","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":370},{"nctId":"NCT01753336","phase":"PHASE3","title":"Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2013-03","conditions":"Cervical Dystonia","enrollment":112},{"nctId":"NCT02450526","phase":"PHASE3","title":"Dysport in the Treatment of Glabellar Lines in Chinese Subjects","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-04","conditions":"Glabellar Lines","enrollment":520},{"nctId":"NCT00702754","phase":"PHASE4","title":"An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia","status":"COMPLETED","sponsor":"Solstice Neurosciences","startDate":"2001-06","conditions":"Cervical Dystonia","enrollment":502},{"nctId":"NCT02428608","phase":"PHASE2","title":"Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2015-05","conditions":"Glabellar Frown Lines","enrollment":570},{"nctId":"NCT02184988","phase":"PHASE2","title":"Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2014-08","conditions":"Glabellar Frown Lines","enrollment":352},{"nctId":"NCT03908580","phase":"PHASE4","title":"MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2013-09-06","conditions":"Spasticity, Muscle","enrollment":120},{"nctId":"NCT01256021","phase":"PHASE4","title":"The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2010-08","conditions":"Muscle Spasticity","enrollment":212},{"nctId":"NCT03647982","phase":"PHASE1","title":"Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2018-03-20","conditions":"Anhidrotic Area, Hyperhidrosis","enrollment":13},{"nctId":"NCT03078270","phase":"PHASE4","title":"A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder","status":"TERMINATED","sponsor":"Daniel Lieberman","startDate":"2017-02-01","conditions":"Anxiety Disorder Social, Anxiety","enrollment":4},{"nctId":"NCT02261467","phase":"PHASE3","title":"A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-10-21","conditions":"Forehead Rhytides, Glabellar Rhytides","enrollment":421},{"nctId":"NCT03641950","phase":"PHASE4","title":"The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.","status":"COMPLETED","sponsor":"Hugel","startDate":"2015-04-30","conditions":"Essential Blepharospasm","enrollment":249},{"nctId":"NCT03585569","phase":"PHASE3","title":"\" Treating MS Patients With Lower Extremity Spasticity Using Dysport\"","status":"UNKNOWN","sponsor":"Neurology Center of New England P.C.","startDate":"2018-05-01","conditions":"Multiple Sclerosis, Spasticity, Muscle","enrollment":30},{"nctId":"NCT02191579","phase":"PHASE4","title":"Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-08-05","conditions":"Migraine Disorders","enrollment":282},{"nctId":"NCT01896895","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2013-11","conditions":"Bilateral Blepharospasm (BEB)","enrollment":61},{"nctId":"NCT02008136","phase":"PHASE1","title":"New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain","status":"UNKNOWN","sponsor":"VA Connecticut Healthcare System","startDate":"2016-03","conditions":"Cervicalgia, Low Back Pain","enrollment":60},{"nctId":"NCT01905683","phase":"PHASE3","title":"Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2013-08","conditions":"Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy","enrollment":370},{"nctId":"NCT01352546","phase":"PHASE1","title":"Botox Injection for Treatment of Vaginismus","status":"COMPLETED","sponsor":"Plastic Surgery Professional Association","startDate":"2010-08","conditions":"Vaginismus","enrollment":31},{"nctId":"NCT03193359","phase":"PHASE3","title":"Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2018-01-15","conditions":"Migraine Disorders","enrollment":""},{"nctId":"NCT03175263","phase":"","title":"OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2008-09-01","conditions":"Chronic Migraine","enrollment":57},{"nctId":"NCT00460564","phase":"PHASE3","title":"Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Post-Stroke Spasticity, Cerebrovascular Accident","enrollment":109},{"nctId":"NCT01603459","phase":"PHASE3","title":"Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2012-05","conditions":"Spasticity of the Upper and Lower Limb Due to Cerebral Causes","enrollment":155},{"nctId":"NCT01205451","phase":"PHASE3","title":"A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Spasticity, Post-Stroke","enrollment":109},{"nctId":"NCT01392300","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2011-09","conditions":"Post-stroke Spasticity of the Upper Limb","enrollment":317},{"nctId":"NCT01464307","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2011-12","conditions":"Post-stroke Spasticity of the Lower Limb","enrollment":290},{"nctId":"NCT01920945","phase":"PHASE2","title":"OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study","status":"TERMINATED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2014-09","conditions":"New Daily Persistent Headache","enrollment":6},{"nctId":"NCT01575054","phase":"PHASE3","title":"BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-05","conditions":"Muscle Spasticity","enrollment":468},{"nctId":"NCT01997983","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2013-11","conditions":"Interstitial Cystitis, IC","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":415,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BoNT/A-DP"],"phase":"phase_3","status":"active","brandName":"Botulinum Toxin A - Open Label","genericName":"Botulinum Toxin A - Open Label","companyName":"Croma-Pharma GmbH","companyId":"croma-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum Toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}